Cargando…
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients
Colorectal cancer (CRC) is the third most prevalent cancer type worldwide with a mortality rate of approximately 50%. Elevated cell-surface expression of truncated carbohydrate structures such as Tn antigen (GalNAcα-Ser/Thr) is frequently observed during tumor progression. We have previously demonst...
Autores principales: | Lenos, Kristiaan, Goos, Jeroen A.C.M., Vuist, Ilona M., den Uil, Sjoerd H., Delis-van Diemen, Pien M., Belt, Eric J.Th., Stockmann, Hein B.A.C., Bril, Herman, de Wit, Meike, Carvalho, Beatriz, Giblett, Susan, Pritchard, Catrin A., Meijer, Gerrit A., van Kooyk, Yvette, Fijneman, Remond J.A., van Vliet, Sandra J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694901/ https://www.ncbi.nlm.nih.gov/pubmed/26172302 |
Ejemplares similares
-
MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer
por: van den Broek, Evert, et al.
Publicado: (2018) -
Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study
por: den Uil, Sjoerd H., et al.
Publicado: (2019) -
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence
por: den Uil, Sjoerd H, et al.
Publicado: (2016) -
Lumican and Versican Are Associated with Good Outcome in Stage II and III Colon Cancer
por: de Wit, Meike, et al.
Publicado: (2012) -
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
por: Nugteren, Sandrine, et al.
Publicado: (2022)